Affordable Access

deepdyve-link
Publisher Website

Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.

Authors
  • Mehling, Matthias
  • Kappos, Ludwig
  • Derfuss, Tobias
Type
Published Article
Journal
Current Neurology and Neuroscience Reports
Publisher
Springer-Verlag
Publication Date
Oct 01, 2011
Volume
11
Issue
5
Pages
492–497
Identifiers
DOI: 10.1007/s11910-011-0216-9
PMID: 21789537
Source
Medline
License
Unknown

Abstract

The oral sphingosine 1-phosphate receptor (S1PR) modulator fingolimod functionally antagonizes S1PR hereby blocking lymphocyte egress from secondary lymphoid organs to the peripheral blood circulation. This results in a reduction in peripheral lymphocyte counts, including potentially encephalitogenic T cells. In patients with relapsing multiple sclerosis fingolimod has been shown to be an effective treatment. In phase 2 and phase 3 studies fingolimod-treated patients had reduced disease activity clinically and in MRI. Although severe infectious complications occurred in single cases treated with fingolimod, the frequency of overall infections was comparable in fingolimod-treated patients and controls. Overall, in clinical studies fingolimod was well tolerated and had a favorable safety profile. In follow-up studies with continuous fingolimod, treatment showed sustained efficacy while being well tolerated.

Report this publication

Statistics

Seen <100 times